Skip to main content

NCT01343277 - A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma

A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma


CSR Summary

Not Yet Available


Data Specification

Not Available


Annotated CRF

Not Available

Data Request Dashboard

Operations

No data requests found. Click here to generate a new one.

Product Info

Generic Name
Trabectedin
Product Name
YONDELIS®
Therapeutic Area
Cancers and Other Neoplasms
Enrollment
577
% Female
70.0%
% White
N/A
Product Class
Antineoplastic Agents
Sponsor Protocol Number
ET743-SAR-3007
Data Holder
Johnson & Johnson
Condition Studied
Liposarcoma/Leiomyosarcoma, Advanced
Mean/Median Age (Years)
57.0

Supporting Documentation

Data Definition Specification Available
Annotated Case Report Form Available
Clinical Study Report
Collected Datasets
Data Definition Specification
Protocol with Amendments
Statistical Analysis Plan
Study Phase 
3

Disclaimer

Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.